Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05UGC
|
|||
| Former ID |
DIB020461
|
|||
| Drug Name |
muramyl dipeptide
|
|||
| Synonyms |
Muramyl Dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; muramyldipeptide; CHEBI:59414; MurNAc-L-Ala-gamma-D-Glu; Acetylmuramyl-L-alanyl-D-isoglutamine; Acetylmuramyl-alanyl-isoglutamine; 87420-48-2; 53678-77-6; (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-Acetamido-2-(Hydroxymethyl)-3,6-Bis(Oxidanyl)oxan-4-Yl]oxypropanoyl]amino]propanoyl]amino]-5-Azanyl-5-Oxidanylidene-Pentanoic Acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C19H32N4O11
|
|||
| Canonical SMILES |
CC(C(=O)NC(CCC(=O)O)C(=O)N)NC(=O)C(C)OC1C(C(OC(C1O)CO)O)NC(=O)C
|
|||
| InChI |
1S/C19H32N4O11/c1-7(17(30)23-10(16(20)29)4-5-12(26)27)21-18(31)8(2)33-15-13(22-9(3)25)19(32)34-11(6-24)14(15)28/h7-8,10-11,13-15,19,24,28,32H,4-6H2,1-3H3,(H2,20,29)(H,21,31)(H,22,25)(H,23,30)(H,26,27)/t7-,8+,10+,11+,13+,14+,15+,19+/m0/s1
|
|||
| InChIKey |
BSOQXXWZTUDTEL-ZUYCGGNHSA-N
|
|||
| CAS Number |
CAS 87420-48-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:59414
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NLR pyrin domain containing 1 (NLRP1) | Target Info | Agonist | [2] |
| Pattern recognition receptor NOD2 (NOD2) | Target Info | Agonist | [3] | |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| TNF signaling pathway | ||||
| Shigellosis | ||||
| Tuberculosis | ||||
| Inflammatory bowel disease (IBD) | ||||
| Pathway Interaction Database | Canonical NF-kappaB pathway | |||
| Reactome | NOD1/2 Signaling Pathway | |||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| Interleukin-1 signaling | ||||
| activated TAK1 mediates p38 MAPK activation | ||||
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | ||||
| WikiPathways | MAP kinase activation in TLR cascade | |||
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | ||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | ||||
| Interleukin-1 signaling | ||||
| NOD pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5024). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1768). | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1763). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.